Compare Intuitive Surgical, Inc. (ISRG) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intuitive Surgical, Inc. vs Travere Therapeutics Inc. Common Stock — how do they compare? Intuitive Surgical, Inc. trades at $424.38 (market cap $148.46B), while Travere Therapeutics Inc. Common Stock trades at $53.44 (market cap $5.02B). The key difference: Intuitive Surgical, Inc. is far larger — about 29.6× Travere Therapeutics Inc. Common Stock's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Intuitive Surgical, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Intuitive Surgical, Inc. for 84 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| ISRG | TVTX | |
|---|---|---|
Market Cap | $148.46B | $5.02B |
Volume | 1,914,576 | 2,060,842 |
Sector | Health | Health |
52-Week High | $592.85 | $67.52 |
52-Week Low | $332.02 | $26.79 |
Typical Hold Time | 84 Days | 0 Days |
Enterprise Value | $143.25B | $5.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intuitive Surgical (ISRG) trades at $422.06, down 1.3% on the day, as the stock faces short-term pressure amid concerns about procedure growth. The company maintains strong fundamentals with 2025 revenue reaching $10.06 billion and net income of $2.86 billion, representing 28.45% margins. Technical indicators show a bullish trend with support at $418 and resistance at $431, while analyst consensus remains strongly positive with a $480.78 price target.
ISRG's dominant position in robotic surgery and expanding international presence provide long-term growth potential, though near-term headwinds include China weakness and affordability pressures. The stock's premium valuation (P/E 48.19) requires continued execution, but recurring revenue from instruments and services supports stability. International expansion in India and Japan offers offsetting growth opportunities.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Intuitive Surgical, Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
